We are live on
!
Find out more
AAA
Affinity Asset Advisors Portfolio holdings
AUM
$1.94B
1-Year Est. Return
374.45%
This Fund
S&P 500
This Quarter
Est. Return
-0.2%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$279M
AUM Growth
-$15.1M
(-5.1%)
Cap. Flow
-$10.5M
Cap. Flow
% of AUM
-3.76%
Top 10 Holdings %
Top 10 Hldgs %
54.03%
Holding
87
New
14
Increased
26
Reduced
16
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
VINC
Vincerx Pharma, Inc. Common Stock
VINC
|
+$4.5M |
| 2 |
Zentalis Pharmaceuticals
ZNTL
|
+$3.48M |
| 3 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
+$3.39M |
| 4 |
Protagonist Therapeutics
PTGX
|
+$2.97M |
| 5 |
MSAC
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
|
+$2.93M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Travere Therapeutics
TVTX
|
+$5.49M |
| 2 |
Curis
CRIS
|
+$3.95M |
| 3 |
MSACU
Medicus Sciences Acquisition Corp. Unit
MSACU
|
+$2.96M |
| 4 |
SNCE
Science 37 Holdings, Inc. Common Stock
SNCE
|
+$2.54M |
| 5 |
Celldex Therapeutics
CLDX
|
+$2.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 67.7% |
| 2 | Financials | 3.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
76
Travere Therapeutics
TVTX
$5.17B
| – | – |
-220,000
| Closed | -$5.49M |
|
77
CALL
Vertex Pharmaceuticals
VRTX
$122B
| – | – |
-50,000
| Closed | -$10.7M |
|
|
WINT
78
DELISTED
Windtree Therapeutics
WINT
| – | – |
-1
| Closed | -$105K |
|
79
X4 Pharmaceuticals
XFOR
$346M
| – | – |
-2,500
| Closed | -$646K |
|
|
ASLN
80
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
| – | – |
-5,000
| Closed | -$670K |
|
|
ZYNE
81
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
| – | – |
-13,285
| Closed | -$62K |
|
|
RUBY
82
CALL
DELISTED
Rubius Therapeutics, Inc
RUBY
| – | – |
-70,000
| Closed | -$1.85M |
|
|
EPZM
83
DELISTED
Epizyme, Inc
EPZM
| – | – |
-50,000
| Closed | -$436K |
|
|
VINCW
84
DELISTED
Vincerx Pharma, Inc. Warrant
VINCW
| – | – |
-218,000
| Closed | -$881K |
|
|
MSACU
85
DELISTED
Medicus Sciences Acquisition Corp. Unit
MSACU
| – | – |
-300,000
| Closed | -$2.96M |
|
Similar funds
FM
1SB
HCL
OCM
MWA
AF
NFG
HC
Affinity Asset Advisors's Q2 2021 Portfolio in Review
As of Q2 2021, Affinity Asset Advisors held 87 positions worth $279M, down 5.1% from $294M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Affinity Asset Advisors withdrew a net $10.5M in Q2 2021, closing 18 positions and reducing 16 holdings. Its most notable exit was Travere Therapeutics, an estimated $5.49M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 68% of assets, up from 63% a quarter earlier, followed by Financials.
Against the trend, Affinity Asset Advisors opened a new position in Medicus Sciences Acquisition Corp. Class A Ordinary Share worth $2.9M.
- Affinity Asset Advisors's largest Q2 2021 buy was Medicus Sciences Acquisition Corp. Class A Ordinary Share: 300,000 shares worth $2.9M.
- Affinity Asset Advisors added most to Vincerx Pharma, Inc. Common Stock in Q2 2021, an estimated $4.5M increase.
- Affinity Asset Advisors's biggest Q2 2021 reduction was Curis, cutting an estimated $3.95M.
- Affinity Asset Advisors fully exited Travere Therapeutics in Q2 2021, selling an estimated $5.49M.
- Affinity Asset Advisors's ten largest holdings make up 54% of its $279M portfolio in Q2 2021.
- Affinity Asset Advisors opened 14 new positions and closed 18 in Q2 2021.
- Affinity Asset Advisors's portfolio value fell 5.1% quarter-over-quarter to $279M.
Based on Affinity Asset Advisors's 13F filing for Q2 2021, filed 13 Aug 2021.